You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | 0.0% | n/a |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -87.0 | 0.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 0.0 | 0.0 |
| Price / Book value | 53.0 |
| Latest | Forecast | |
|---|---|---|
| Revenue | n/a | 0.0% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | 0.0% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2018-06-30 | n/a | -1.72 | -2.50p | -16.0 | 0.0 | n/a | n/a | 0.0% |
| 2019-06-30 | n/a | -1.68 | -2.50p | -8.7 | 0.0 | n/a | n/a | 0.0% |
| 2020-06-30 | 0.05 | -1.12 | -1.50p | -17.5 | 0.0 | n/a | n/a | 0.0% |
| 2021-06-30 | n/a | -1.72 | -2.50p | -115.0 | 0.0 | n/a | n/a | 0.0% |
| Sareum progresses Covid-19 and autoimmune treatment candidate Sharecast News | 16 Mar |
|---|
| Second Price Monitoring Extn | 30-Sep-22 16:45 |
|---|---|
| Price Monitoring Extension | 30-Sep-22 16:40 |
| Sareum notes FDA approval of first TYK2 Inhibitor | 12-Sep-22 07:00 |
| CTA application to MHRA and Corporate Update | 28-Jul-22 07:00 |